Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)
South Korea
· Delayed Price · Currency is KRW 6,340.00
-10.00 (-0.16%)
At close: Apr 28, 2026
Sinil Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 7,531 | 14,301 | 13,641 | 12,157 | 6,679 | Upgrade
|
| Depreciation & Amortization | 5,991 | 5,607 | 5,361 | 4,432 | 4,536 | Upgrade
|
| Loss (Gain) From Sale of Assets | 24.33 | -3.72 | 641.55 | -221.3 | -14 | Upgrade
|
| Asset Writedown & Restructuring Costs | -108.28 | -31 | 7 | 92.08 | -14.5 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.34 | 26.81 | 532.61 | 373.44 | -115.48 | Upgrade
|
| Provision & Write-off of Bad Debts | 34.21 | 797.59 | 446.86 | 409.12 | 160.62 | Upgrade
|
| Other Operating Activities | -191.6 | 3,161 | -408.83 | 2,903 | 2,102 | Upgrade
|
| Change in Accounts Receivable | 452 | 855.22 | 1,095 | -3,247 | 161.49 | Upgrade
|
| Change in Inventory | -147.89 | -369.61 | -2,304 | -3,487 | 236.85 | Upgrade
|
| Change in Accounts Payable | -446.88 | -113.72 | -1,271 | 1,840 | 1,210 | Upgrade
|
| Change in Other Net Operating Assets | -1,548 | -1,541 | -2,587 | -1,563 | -3,779 | Upgrade
|
| Operating Cash Flow | 11,589 | 22,689 | 15,154 | 13,688 | 11,163 | Upgrade
|
| Operating Cash Flow Growth | -48.92% | 49.72% | 10.72% | 22.61% | 0.92% | Upgrade
|
| Capital Expenditures | -3,145 | -10,362 | -13,604 | -10,351 | -3,343 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 74.92 | 122.76 | 316.6 | 145.68 | Upgrade
|
| Sale (Purchase) of Intangibles | -767.92 | -94.64 | -57 | -27.5 | -285.65 | Upgrade
|
| Investment in Securities | -971.61 | -13,268 | 2,510 | -4,880 | -3,103 | Upgrade
|
| Other Investing Activities | 32 | 176.53 | -291.6 | 62.27 | -95 | Upgrade
|
| Investing Cash Flow | -4,803 | -23,473 | -11,319 | -14,880 | -6,665 | Upgrade
|
| Short-Term Debt Issued | - | - | 22,578 | - | - | Upgrade
|
| Total Debt Issued | - | - | 22,578 | - | - | Upgrade
|
| Short-Term Debt Repaid | - | - | -22,578 | - | - | Upgrade
|
| Long-Term Debt Repaid | -149.49 | -147.23 | -154.09 | -133.75 | -127.98 | Upgrade
|
| Total Debt Repaid | -149.49 | -147.23 | -22,732 | -133.75 | -127.98 | Upgrade
|
| Net Debt Issued (Repaid) | -149.49 | -147.23 | -154.09 | -133.75 | -127.98 | Upgrade
|
| Repurchase of Common Stock | - | - | -73.39 | -104.49 | -168.43 | Upgrade
|
| Dividends Paid | -2,196 | -1,965 | -1,112 | -1,081 | -1,051 | Upgrade
|
| Other Financing Activities | 222 | -24 | 92 | - | -0 | Upgrade
|
| Financing Cash Flow | -2,124 | -2,136 | -1,248 | -1,319 | -1,347 | Upgrade
|
| Foreign Exchange Rate Adjustments | 7.5 | 44.83 | -11.37 | 114.94 | 25.44 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | -0 | - | - | Upgrade
|
| Net Cash Flow | 4,670 | -2,876 | 2,576 | -2,396 | 3,176 | Upgrade
|
| Free Cash Flow | 8,444 | 12,327 | 1,551 | 3,336 | 7,820 | Upgrade
|
| Free Cash Flow Growth | -31.50% | 694.85% | -53.52% | -57.34% | 245.93% | Upgrade
|
| Free Cash Flow Margin | 10.48% | 13.78% | 1.74% | 4.17% | 12.66% | Upgrade
|
| Free Cash Flow Per Share | - | 1066.39 | 134.13 | 299.94 | 695.63 | Upgrade
|
| Cash Interest Paid | 19.71 | 26.97 | 26.13 | 6.05 | 9.72 | Upgrade
|
| Cash Income Tax Paid | 3,145 | 468.26 | 3,081 | 772.84 | 1,113 | Upgrade
|
| Levered Free Cash Flow | 5,309 | 8,588 | -2,857 | 148.73 | 8,141 | Upgrade
|
| Unlevered Free Cash Flow | 5,321 | 8,605 | -2,840 | 152.52 | 8,147 | Upgrade
|
| Change in Working Capital | -1,691 | -1,169 | -5,067 | -6,457 | -2,170 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.